<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There have been several reports concerning elevated <z:chebi fb="105" ids="17234">glucose</z:chebi> 6 phosphate dehydrogenase (G6PDH), the rate-limiting enzyme of <z:chebi fb="0" ids="25901">pentose</z:chebi> phosphate pathway (PPP), in experimental muscle disturbances </plain></SENT>
<SENT sid="1" pm="."><plain>PPP produces <z:chebi fb="1" ids="33942">ribose</z:chebi>, a substrate of <z:chebi fb="40" ids="33697">RNA</z:chebi>, and <z:chebi fb="1" ids="16474">NADPH</z:chebi> which is a cofactor of fatty acid synthesis </plain></SENT>
<SENT sid="2" pm="."><plain>PPP also has a role of by-path pathway of glycolysis </plain></SENT>
<SENT sid="3" pm="."><plain>Then, we evaluated G6PDH activity and <z:chebi fb="40" ids="33697">RNA</z:chebi> content in biopsied quadriceps muscle </plain></SENT>
<SENT sid="4" pm="."><plain>The subjects were muscles from 23 neurogenic <z:hpo ids='HP_0003202'>amyotrophy</z:hpo>, 54 <z:hpo ids='HP_0003198'>myopathy</z:hpo> including 19 progressive <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> (PMD), and 10 controls whose muscle was obtained at orthopedic surgery </plain></SENT>
<SENT sid="5" pm="."><plain>Neurogenic <z:hpo ids='HP_0003202'>amyotrophy</z:hpo> consisted of 12 <z:hpo ids='HP_0007354'>amyotrophic lateral sclerosis</z:hpo> (ALS), 4 <z:hpo ids='HP_0007269'>spinal muscular atrophy</z:hpo> and 7 peripheral nerve disorders </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0003198'>Myopathy</z:hpo> were 3 Duchenne <z:mpath ids='MPATH_554'>dystrophy</z:mpath>, 2 <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, 8 limb-girdle type <z:mpath ids='MPATH_554'>dystrophy</z:mpath>, 6 facio-scapular +-humeral <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo>, 6 myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath>, 6 <z:hpo ids='HP_0003737'>mitochondrial myopathy</z:hpo>, 5 endocrinological <z:hpo ids='HP_0003198'>myopathy</z:hpo>, 3 hypokalemic <z:hpo ids='HP_0003198'>myopathy</z:hpo>, 8 polymyositis and 4 other <z:hpo ids='HP_0009071'>inflammatory myopathy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The assays of G6PDH and <z:chebi fb="40" ids="33697">RNA</z:chebi> were performed after Glock's and Fleck's methods, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The control values were 3.6 +/- 0.8 nmol formed <z:chebi fb="1" ids="16474">NADPH</z:chebi>/mg protein/min (M +/- SD) in G6PDH and 0.69 +/- 0.17 micrograms/mg non-collagen protein in <z:chebi fb="40" ids="33697">RNA</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Most cases of PMD, as well as some cases of ALS, <z:hpo ids='HP_0000836'>hyperthyroidism</z:hpo>, mitochondria hypokalemic <z:hpo ids='HP_0003198'>myopathy</z:hpo>, <z:hpo ids='HP_0009071'>inflammatory myopathy</z:hpo> showed increased values (beyond M + 2SD of control) both in G6PDH and <z:chebi fb="40" ids="33697">RNA</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>There were significant positive correlations between G6PDH activity and <z:chebi fb="40" ids="33697">RNA</z:chebi> content in PMD and <z:e sem="disease" ids="C0085084" disease_type="Disease or Syndrome" abbrv="">motor neuron disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> showed <z:mpath ids='MPATH_458'>normal</z:mpath> values in both G6PDH and <z:chebi fb="40" ids="33697">RNA</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Half number of cases of <z:hpo ids='HP_0003737'>mitochondrial myopathy</z:hpo> demonstrated increased G6PDH alone.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>